Press Releases AbbVie Inc.

Stocks

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 17:37:17 11/06/2026 BST			5-day change	1st Jan Change
225.71 ^USD	+0.34%		+0.47%	-1.09%

06-10	Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon	RE
06-09	AbbVie Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:40 AM

Press Releases

06-08	AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026	PR
06-02	AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference	PR
06-01	AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia	AQ
05-29	AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia	PR
05-27	U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options	PR
05-22	AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection	PR
05-21	AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline	PR
05-21	Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults	PR
05-06	AbbVie to Present at the Bank of America Securities Healthcare Conference	PR
05-05	AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®	PR
05-04	SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis	AQ
04-30	AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec	GL
04-30	Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month	PR
04-29	AbbVie : ABBV 1Q26 Press Release Final	PU
04-29	AbbVie: Q1 Earnings Snapshot	AQ
04-29	AbbVie Reports First-Quarter 2026 Financial Results	PR
04-28	AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata	PR
04-28	RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor	AQ
04-27	AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease	PR
04-24	AbbVie Provides Update on TrenibotulinumtoxinE Biologics License Application in the U.S.	AQ
04-23	AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.	PR
04-22	AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus	PR
04-20	AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada	AQ
04-14	Erin Lichy Gets Real About Her Natrelle® Breast Augmentation	PR
04-13	AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE) in Platinum-Sensitive Ovarian Cancer (PSOC) at SGO 2026	AQ